Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INCR -- Incara Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (180)	8/19/2002 9:16:54 PM
From: mopgcw	Respond to of 196

Reported: August 14 Incara Pharmaceuticals Corp. (INCR) Incara Pharmaceuticals said it will restated its balance sheet as of the fiscal year ended Sept. 30, 2001, due to a reclassification of its series C redeemable convertible exchangeable preferred stock outside of permanent stockholders' equity to the mezzanine section. The company said the reclassification doesn't affect the net loss for any period, or affect the company's cash flow or cash position for any period. Reported: August 13